Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML

WHY IT MATTERS: Patients with chronic jaw and facial pain who have not found relief through standard treatments now have emerging clinical trial evidence supporting sublingual cannabis extracts as a potential therapeutic option worth discussing with their provider. CLINICAL OVERVIEW: Sublingual cannabis extract administration has demonstrated meaningful reductions in myofascial pain among patients with temporomandibular disorders, a condition historically resistant to conventional pharmacological approaches. The findings add to a growing body of evidence supporting cannabinoid-based interventions for chronic orofacial pain, where inflammation and central sensitization play significant roles.

Read More

Success Kid

Got prescribed cannabis for chronic pain. Actually read the dosing guidelines and didn’t immediately text everyone about it. Further Reading Cannabis NewsRecreational drugs triple the risk of stroke in young people, study...

Read More

Batman Slapping Robin

“Maybe we should try CBD for inflammation.” Batman: “That’s literally what the clinical evidence supports.” Robin gets slapped anyway because evidence-based medicine is apparently still controversial. Further Reading Cannabis NewsRecreational drugs triple...

Read More